<DOC>
	<DOCNO>NCT02686281</DOCNO>
	<brief_summary>The purpose study determine toxicity , tolerability safety single ascend dos GMC-252-L-Lysine Salt healthy male subject .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study New Drug Type 2 Diabetes</brief_title>
	<detailed_description />
	<criteria>Body Mass Index ( BMI ) within range 1835 kg/m2 inclusive . BMI = Body weight ( kg ) / [ Height ( ) ] 2 . Diet : Able eat standard food , vegetarian . Compliance : Understood willing , able likely comply study procedure restriction . Consent : Demonstrated understand study willingness participate evidence voluntary write informed consent receive sign date copy Informed Consent Form . Had know hypersensitivity diflunisal , NAC ( Nacetylcysteine ) nonsteroidal antiinflammatory drug ( NSAIDs ) . Had know peptic ulcer disease . Had estimate creatinine ( CREA ) clearance ≥ 50 mL/min ( Creatinine clearance calculate serum CREA value use Cockroft &amp; Gault formula ) . Had history heart failure uncontrolled hypertension know overt cardiovascular disease . Had history 'Aspirin Triad ' ( chronic rhinosinusitis polyp , severe asthma intolerance aspirin NSAIDs ) . Had mark abnormality liver test entry study . Male subject willing use effective method contraception , applicable ( unless anatomically sterile abstain sexual intercourse line prefer usual lifestyle subject ) Day 1 3 month afterwards . Subject clinically significant abnormal serum biochemistry , haematology urine examination value Screening Visit . Subject negative urinary drug abuse screen ( positive alcohol result could repeat discretion Investigator ) . Subject negative human immunodeficiency virus ( HIV ) Hepatitis B ( Hep B ) Hepatitis C ( Hep C ) result . Subject clinically significant abnormality 12lead ECG Screening Visit . Subject available complete study ( include Followup Visits ) . Subject satisfy medical examiner fitness participate study . Subjects nonsmoker nonalcohol drinker drink alcohol moderation ( e.g . ≤ 14 units/week ) . A clinically significant history gastrointestinal disorder likely influence drug absorption . Receipt regular medication Screening Visit may impact safety objective study ( Investigator 's discretion ) . Evidence renal , hepatic , central nervous system , respiratory , cardiovascular metabolic dysfunction . A clinically significant history previous allergy/sensitivity GMC252 . A clinically significant history drug alcohol abuse . Inability communicate well Investigator ( i.e. , language problem , poor mental development impair cerebral function ) . Participation New Chemical Entity clinical study within previous 16 week market drug clinical study within previous 12 week . ( N.B . washout period trial define period time elapse last dose previous study first dose next study ) . Donation 450 mL blood within previous 12 week . Receipt medication since Screening Visit may impact safety objective study ( Investigator 's discretion ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>